Matson To Attend Stifel Transportation & Logistics Conference
Get Alerts MATX Hot Sheet
Overall Analyst Rating:
NEUTRAL ( Up)
Dividend Yield: 1.1%
Revenue Growth %: +5.0%
Join SI Premium – FREE
HONOLULU, Feb. 3, 2021 /PRNewswire/ -- Matson, Inc. (NYSE: MATX) announced today that Matt Cox, Chairman and Chief Executive Officer, and Joel Wine, Senior Vice President and Chief Financial Officer, will be attending the Stifel Transportation and Logistics Conference to be held virtually on February 10, 2021.
Matson will provide access to the presentation slides on its website on February 10, 2021. Access to the slides will be available on www.matson.com, under Investors.
About the Company Founded in 1882, Matson (NYSE: MATX) is a leading provider of ocean transportation and logistics services. Matson provides a vital lifeline to the domestic non-contiguous economies of Hawaii, Alaska, and Guam, and to other island economies in Micronesia. Matson also operates two premium, expedited services from China to Long Beach, California, provides service to Okinawa, Japan and various islands in the South Pacific, and operates an international export service from Dutch Harbor to Asia. The Company's fleet of owned and chartered vessels includes containerships, combination container and roll-on/roll-off ships and custom-designed barges. Matson Logistics, established in 1987, extends the geographic reach of Matson's transportation network throughout the continental U.S. Its integrated, asset-light logistics services include rail intermodal, highway brokerage, warehousing, freight consolidation, Asia supply chain services, and forwarding to Alaska. Additional information about the Company is available at www.matson.com.
Investor Relations inquiries: | News Media inquiries: |
Lee Fishman | Keoni Wagner |
Matson, Inc. | Matson, Inc. |
510.628.4227 | 510.628.4534 |
View original content to download multimedia:http://www.prnewswire.com/news-releases/matson-to-attend-stifel-transportation--logistics-conference-301221771.html
SOURCE Matson, Inc.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Novartis radioligand therapy Lutathera® FDA approved as first medicine specifically for pediatric patients with gastroenteropancreatic neuroendocrine tumors
- VTYX DEADLINE: ROSEN, TRUSTED INVESTOR COUNSEL, Encourages Ventyx Biosciences, Inc. Investors to Secure Counsel Before Important April 30 Deadline in Securities Class Action – VTYX
- From 'the big one' to big relief for Adena Health heart attack patient
Create E-mail Alert Related Categories
PRNewswire, Press ReleasesRelated Entities
StifelSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!